Belgian biotech ThromboGenics has announced it will change its name to Oxurion in the next few weeks. The stock ticker symbol will change to OXUR.
Chief executive Patrik De Haes said: “The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders,” and “we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options.”
Source: The Pharma Letter
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
